Drug Trial Radar · NCT00003603
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Sep 20, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
660
Planned (sponsor's estimate)
Start
Mar 1998
Primary completion
Not stated
Sponsor
- Lead sponsor
- Riverside Haematology GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Steroids, such as dexamethasone or prednisolone, may help relieve some of the side effects of chemotherapy. It is not yet known which regimen of chemotherapy plus steroid therapy is more effective in treating patients with multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of chemotherapy plus steroid therapy in treating patients with multiple myeloma that has recurred for the first time.
Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cyclophosphamideDrug
dexamethasoneDrug
idarubicinDrug
lomustineDrug
melphalanDrug
prednisoloneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hammersmith Hospital
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.